RESOLVE
Regimen
- Experimental
- perioperative SOX, or adjuvant SOX
- Control
- adjuvant CapOx
Population
Chinese patients with cT4aN+ or cT4bNany M0 gastric/GEJ cancer after D2 gastrectomy
Key finding
3y DFS 59.4% (periop-SOX) vs 51.1% (adj-CapOx), HR 0.77 (95% CI 0.61-0.97, p=0.028); adj-SOX 56.5% non-inferior to adj-CapOx
Source: PMID 34252374
Timeline
Guideline citations
- NCCN GASTRIC (p.136)
- CSCO GASTRIC 2025 (p.63)⚠️ OCR source